Literature DB >> 2573579

Amplification of c-myc and c-erbB-2 proto-oncogenes in human solid tumors: frequency and clinical significance.

M Gutman1, Y Ravia, D Assaf, T Yamamoto, R Rozin, Y Shiloh.   

Abstract

Molecular probes for cellular proto-oncogenes have recently been extensively used in order to search for functional and structural alterations in tumor tissues. Variable, and sometimes contradictory, results have been obtained regarding the frequency and clinical significance of amplification of the c-myc and c-erbB-2 proto-oncogenes in different series of human solid tumors. We addressed this question by performing Southern blotting analysis on 131 primary adult solid tumors of various tissues and 5 metastases of unknown origin, using molecular probes for both genes. Amplification of c-myc was found in 5 of the primary tumors, and amplification of c-erbB-2 in 5 others. In 2 tumors of the latter group, the c-erbB-2 gene was also rearranged. The distribution of these 10 tumors with regard to clinical stage and course of the disease did not point to an association between the amplification events and specific stage or prognosis. We concluded that, in this series, the amplification of both proto-oncogenes was occasional and was not a prognostic marker.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2573579     DOI: 10.1002/ijc.2910440509

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  HER-2/neu overexpression is an independent prognostic factor in colorectal cancer.

Authors:  Dong Il Park; Mun Su Kang; Suk Joong Oh; Hong Joo Kim; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim; Won Kon Han; Hungdai Kim; Seung Ho Ryu; Antonia R Sepulveda
Journal:  Int J Colorectal Dis       Date:  2006-09-01       Impact factor: 2.571

Review 2.  How malignant is malignant? A brief review of the microscopic assessment of human neoplasms, and the prediction of whether they will metastasize and kill.

Authors:  I Carr; N Pettigrew
Journal:  Clin Exp Metastasis       Date:  1991 Mar-Apr       Impact factor: 5.150

3.  C-myc as a predictive marker for chemotherapy in metastatic breast cancer.

Authors:  Nataša Todorović-Raković; Zora Nešković-Konstantinović; Dragica Nikolić-Vukosavljević
Journal:  Clin Exp Med       Date:  2011-11-24       Impact factor: 3.984

4.  C-erbB-2 immunostaining: problems with interpretation.

Authors:  E W Kay; C J Walsh; M Cassidy; B Curran; M Leader
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

5.  Lack of prognostic value of immunoreactivity for p62 oncoprotein in colorectal carcinoma.

Authors:  K Matsumoto; J Yamamoto; T Miura
Journal:  Int J Colorectal Dis       Date:  1993-07       Impact factor: 2.571

6.  HER2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies.

Authors:  A H Arnaout; P M Dawson; S Soomro; P Taylor; N A Theodorou; M Feldmann; B M Fendly; H M Shepard; S Shousha
Journal:  J Clin Pathol       Date:  1992-08       Impact factor: 3.411

7.  Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma.

Authors:  J Jaehne; C Urmacher; H T Thaler; H Friedlander-Klar; C Cordon-Cardo; H J Meyer
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

8.  Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer.

Authors:  N R Lemoine; S Jain; F Silvestre; C Lopes; C M Hughes; E McLelland; W J Gullick; M I Filipe
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

9.  c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis.

Authors:  C A Schroeter; C R De Potter; K Rathsmann; R G Willighagen; J C Greep
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

10.  Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma.

Authors:  R J Gilbertson; A D Pearson; R H Perry; E Jaros; P J Kelly
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.